Targeting EBV‐encoded products: Implications for drug development in EBV‐associated diseases
出版年份 2023 全文链接
标题
Targeting EBV‐encoded products: Implications for drug development in EBV‐associated diseases
作者
关键词
-
出版物
REVIEWS IN MEDICAL VIROLOGY
Volume -, Issue -, Pages -
出版商
Wiley
发表日期
2023-10-31
DOI
10.1002/rmv.2487
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Advances for pharmacological activities of Polygonum cuspidatum - A review
- (2023) Jia Ke et al. PHARMACEUTICAL BIOLOGY
- Contribution of Epstein–Barr Virus Lytic Proteins to Cancer Hallmarks and Implications from Other Oncoviruses
- (2023) Mike Dorothea et al. Cancers
- Immunotherapy for nasopharyngeal carcinoma: Current status and prospects (Review)
- (2023) Huageng Huang et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- A bivalent Epstein-Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice
- (2022) Chih-Jen Wei et al. Science Translational Medicine
- How Does Epstein–Barr Virus Interact With Other Microbiomes in EBV-Driven Cancers?
- (2022) Yuxi Wen et al. Frontiers in Cellular and Infection Microbiology
- JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies
- (2022) Bilal Rah et al. Frontiers in Pharmacology
- The eIF4A Inhibitor Silvestrol Blocks the Growth of Human Glioblastoma Cells by Inhibiting AKT/mTOR and ERK1/2 Signaling Pathway
- (2022) Wei Zhang et al. Journal of Oncology
- PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
- (2022) Yan Peng et al. Frontiers in Oncology
- PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
- (2022) Wei Xie et al. Biomedicines
- EBV-associated diseases: Current therapeutics and emerging technologies
- (2022) Srishti Chakravorty et al. Frontiers in Immunology
- In Vitro Safety, Off-Target and Bioavailability Profile of the Antiviral Compound Silvestrol
- (2022) Susanne Schiffmann et al. Pharmaceuticals
- Targeting G-quadruplexes to achieve antiviral activity
- (2022) Emanuela Ruggiero et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Epstein–Barr Virus (EBV) Epithelial Associated Malignancies: Exploring Pathologies and Current Treatments
- (2022) Oren Shechter et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma
- (2021) David Johnson et al. ORAL ONCOLOGY
- Immunization with Epstein–Barr Virus Core Fusion Machinery Envelope Proteins Elicit High Titers of Neutralizing Activities and Protect Humanized Mice from Lethal Dose EBV Challenge
- (2021) Xinle Cui et al. Vaccines
- Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- (2021) Belal Almajali et al. Pharmaceuticals
- Resveratrol for cancer therapy: Challenges and future perspectives
- (2021) Boxu Ren et al. CANCER LETTERS
- Unlocking G-Quadruplexes as Antiviral Targets
- (2021) Ardavan Abiri et al. PHARMACOLOGICAL REVIEWS
- Molecular Basis of Epstein–Barr Virus Latency Establishment and Lytic Reactivation
- (2021) Takayuki Murata et al. Viruses-Basel
- Statins affect cancer cell plasticity with distinct consequences for tumor progression and metastasis
- (2021) Madeleine Dorsch et al. Cell Reports
- Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases
- (2021) Xinle Cui et al. Frontiers in Immunology
- Immune System Disorders, Cancer and Viral Infections: A New Treatment Opportunity for the Immune Checkpoint Inhibitors
- (2021) Alejandro Olivares-Hernández et al. Life-Basel
- The different activities of RNA G-quadruplex structures are controlled by flanking sequences
- (2021) Alice J-L Zheng et al. Life Science Alliance
- Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma
- (2020) Shanli Zhu et al. PLoS Pathogens
- KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
- (2020) Michael Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting Epstein-Barr Virus in Nasopharyngeal Carcinoma
- (2020) Pok Man Hau et al. Frontiers in Oncology
- Statin use and safety concerns: an overview of the past, present, and the future
- (2020) Rubina Mulchandani et al. Expert Opinion On Drug Safety
- Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein-Barr virus latent infection and tumor growth
- (2019) Troy E. Messick et al. Science Translational Medicine
- Novel Therapeutics for Epstein–Barr Virus
- (2019) Graciela Andrei et al. MOLECULES
- Epstein-Barr virus strain variation and cancer
- (2019) Teru Kanda et al. CANCER SCIENCE
- Novel cationic Bis(acylhydrazones) as modulators of Epstein–Barr virus immune evasion acting through disruption of interaction between nucleolin and G-quadruplexes of EBNA1 mRNA
- (2019) Oksana Reznichenko et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Prophylactic and therapeutic strategies for Epstein–Barr virus-associated diseases: emerging strategies for clinical development
- (2019) Vijayendra Dasari et al. Expert Review of Vaccines
- Epstein-Barr virus (EBV) activates NKL homeobox gene HLX in DLBCL
- (2019) Stefan Nagel et al. PLoS One
- Thymoquinone (2-Isoprpyl-5-methyl-1, 4-benzoquinone) as a chemopreventive / anticancer agent: Chemistry and Biological effects
- (2019) Anas Ahmad et al. SAUDI PHARMACEUTICAL JOURNAL
- Treatment with Statins in Elderly Patients
- (2019) Ruxandra-Nicoleta Horodinschi et al. Medicina-Lithuania
- CD137 Co-Stimulation Improves The Antitumor Effect Of LMP1-Specific Chimeric Antigen Receptor T Cells In Vitro And In Vivo
- (2019) Xiaojun Tang et al. OncoTargets and Therapy
- Curcumin Inhibits Proliferation of Epstein–Barr Virus-Associated Human Nasopharyngeal Carcinoma Cells by Inhibiting EBV Nuclear Antigen 1 Expression
- (2019) Limei Liu et al. Biomed Research International
- A novel Epstein–Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy
- (2018) Hyun-Il Cho et al. BRITISH JOURNAL OF CANCER
- Counteracting survival functions of EBNA3C in Epstein-Barr virus (EBV)-driven lymphoproliferative diseases by combination of SAHA and bortezomib
- (2018) Kwai Fung Hui et al. Oncotarget
- The Immunomodulatory Capacity of an Epstein-Barr Virus Abortive Lytic Cycle: Potential Contribution to Viral Tumorigenesis
- (2018) Abigail Morales-Sánchez et al. Cancers
- Epstein–Barr Virus-Associated Malignancies: Roles of Viral Oncoproteins in Carcinogenesis
- (2018) Ahmed El-Sharkawy et al. Frontiers in Oncology
- In Cellulo Protein-mRNA Interaction Assay to Determine the Action of G-Quadruplex-Binding Molecules
- (2018) Rodrigo Prado Martins et al. MOLECULES
- Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice
- (2018) Dwain G. van Zyl et al. PLoS Pathogens
- Production of virus-like particles for vaccines
- (2017) J. Fuenmayor et al. New Biotechnology
- Affibody Molecules in Biotechnological and Medical Applications
- (2017) Stefan Ståhl et al. TRENDS IN BIOTECHNOLOGY
- Nucleolin directly mediates Epstein-Barr virus immune evasion through binding to G-quadruplexes of EBNA1 mRNA
- (2017) María José Lista et al. Nature Communications
- EBV induces persistent NF-κB activation and contributes to survival of EBV-positive neoplastic T- or NK-cells
- (2017) Honami Takada et al. PLoS One
- Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases
- (2016) Ajaikumar B Kunnumakkara et al. BRITISH JOURNAL OF PHARMACOLOGY
- Epstein-Barr virus lytic reactivation regulation and its pathogenic role in carcinogenesis
- (2016) Hongde Li et al. International Journal of Biological Sciences
- PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
- (2016) Aaron Goodman et al. Nature Reviews Clinical Oncology
- Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350
- (2016) Xinle Cui et al. VACCINE
- ERK2 phosphorylation of EBNA1 serine 383 residue is important for EBNA1-dependent transactivation
- (2016) Ka-Won Noh et al. Oncotarget
- Novel Epstein-Barr virus-like particles incorporating gH/gL-EBNA1 or gB-LMP2 induce high neutralizing antibody titers and EBV-specific T-cell responses in immunized mice
- (2016) Elizabeth M. Perez et al. Oncotarget
- HDACs and HDAC Inhibitors in Cancer Development and Therapy
- (2016) Yixuan Li et al. Cold Spring Harbor Perspectives in Medicine
- The translation inhibitor silvestrol exhibits direct anti-tumor activity while preserving innate and adaptive immunity against EBV-driven lymphoproliferative disease
- (2015) John T. Patton et al. Oncotarget
- Statins and Cancer
- (2014) Natalia Vallianou et al. Anti-Cancer Agents in Medicinal Chemistry
- Small molecule inhibition of Epstein–Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome
- (2014) Eun Kyung Lee et al. ANTIVIRAL RESEARCH
- Inhibition of Epstein-Barr Virus Lytic Cycle by an Ethyl Acetate Subfraction Separated from Polygonum cuspidatum Root and Its Major Component, Emodin
- (2014) Ching-Yi Yiu et al. MOLECULES
- G-quadruplexes regulate Epstein-Barr virus–encoded nuclear antigen 1 mRNA translation
- (2014) Pierre Murat et al. Nature Chemical Biology
- Cyclin-dependent kinases
- (2014) Marcos Malumbres GENOME BIOLOGY
- Epstein-Barr virus and Burkitt lymphoma
- (2014) Martin Rowe et al. Chinese Journal of Cancer
- Solution Structure of a G-quadruplex Bound to the Bisquinolinium Compound Phen-DC3
- (2013) Wan Jun Chung et al. ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
- From Bortezomib to other Inhibitors of the Proteasome and Beyond
- (2013) Daniela Buac et al. CURRENT PHARMACEUTICAL DESIGN
- Sustained Complete Responses in Patients With Lymphoma Receiving Autologous Cytotoxic T Lymphocytes Targeting Epstein-Barr Virus Latent Membrane Proteins
- (2013) Catherine M. Bollard et al. JOURNAL OF CLINICAL ONCOLOGY
- Dasatinib therapy results in decreased B cell proliferation, splenomegaly, and tumor growth in a murine model of lymphoma expressing Myc and Epstein-Barr virus LMP2A
- (2012) Jamie L. Dargart et al. ANTIVIRAL RESEARCH
- Small molecule and peptide-mediated inhibition of Epstein-Barr virus nuclear antigen 1 dimerization
- (2012) Sun Young Kim et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Statin drug interactions and related adverse reactions
- (2012) Stefano Bellosta et al. Expert Opinion On Drug Safety
- Thymoquinone Efficiently Inhibits the Survival of EBV-Infected B Cells and Alters EBV Gene Expression
- (2012) Malek A. Zihlif et al. INTEGRATIVE CANCER THERAPIES
- Resveratrol Prevents EBV Transformation and Inhibits the Outgrowth of EBV-Immortalized Human B Cells
- (2012) J. Luis Espinoza et al. PLoS One
- New mTOR Targets Grb Attention
- (2011) S. S. Yea et al. SCIENCE
- Dasatinib, a Multikinase Inhibitor: Therapy, Safety, and Appropriate Management of Adverse Events
- (2010) Sepideh Shayani THERAPEUTIC DRUG MONITORING
- STAT3 activation contributes directly to Epstein-Barr virus-mediated invasiveness of nasopharyngeal cancer cellsin vitro
- (2009) Vivian Wai Yan Lui et al. INTERNATIONAL JOURNAL OF CANCER
- Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
- (2009) Regina Cencic et al. PLoS One
- p21 and p27: roles in carcinogenesis and drug resistance
- (2008) Abde M. Abukhdeir et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Stability and kinetics of G-quadruplex structures
- (2008) A. N. Lane et al. NUCLEIC ACIDS RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More